Late Thrombosis of a Drug-eluting Stent Presenting in the Perioperative Period
de Souza, Duncan G. M.D.*; Baum, Victor C. M.D.†; Ballert, Natalie M. M.D.‡
DRUG-ELUTING stents (DES) represent the latest percutaneous coronary intervention (PCI) designed to deal with the problem of in-stent restenosis. These stents are impregnated with a drug (sirolimus or paclitaxel) that retards the neointimal proliferation that leads to restenosis. The thrombogenic profile of DES differs from that of bare metal stents. Postprocedure dual antiplatelet therapy (clopidogrel and aspirin) is required for all types of stents. The recommended duration is 1 month for bare metal stents, 3 months for sirolimus DES, and 6 months for paclitaxel DES.1
Patients are then maintained on lifelong aspirin. Stent thrombosis is described as acute, subacute, or late (> 30 days). An emerging phenomenon is the observation that DES may carry a higher risk of late stent thrombosis. We report a case of perioperative very late stent thrombosis occurring in a patient with a DES.
A 69-yr-old male patient was scheduled to undergo hand-assisted laparoscopic nephroureterectomy for a proximal ureteral tumor. He had coronary artery disease with two paclitaxel DES (Taxus, Boston Scientific Natick, MA) placed 29 months previously. Dual antiplatelet therapy with clopidogrel and aspirin was maintained for 1 yr, after which clopidogrel was stopped and the patient continued to take aspirin. Preoperative assessment showed him to be angina free, with good effort tolerance and no symptoms of congestive heart failure. Consequently, no preoperative cardiac testing was performed. Preoperative medications included metoprolol and atorvastatin, which were taken on the day of surgery. At the request of the surgeon, aspirin was stopped 10 days preoperatively.
Anesthesia induction and maintenance were uneventful. Surgery took 5 h, during which time the patient maintained stable hemodynamics without tachycardia. Blood loss was minimal. The trachea was successfully extubated, and the patient was taken to the postanesthesia care unit. The blood pressure and heart rate remained within normal limits. β-Blockers were not given intraoperatively or in the postanesthesia care unit. After 70 min in the postanesthesia care unit, the bedside nurse noticed ST-segment changes on the monitor. Blood pressure and heart rate were normal, and the patient did not report any chest pain. During preparation for an urgent electrocardiogram, the rhythm deteriorated into ventricular tachycardia without a palpable pulse. The patient was immediately electrically cardioverted. He required a total of four shocks to convert to sinus rhythm. The patient continued to have nonsustained runs of ventricular tachycardia. He was given 2 g magnesium sulfate and 150 mg amiodarone. His blood pressure was 70/40 mmHg. The electrocardiogram demonstrated deep ST-segment depressions across the anterior precordial leads, suggestive of posterior myocardial infarction. With cardiogenic shock secondary to presumed myocardial infarction and an unstable cardiac rhythm, a decision was made to secure the airway and emergently proceed to the cardiac catheterization laboratory. Coronary angiography revealed acute thrombosis at the site of his paclitaxel DES in the proximal circumflex artery (fig. 1
). The paclitaxel DES in the left anterior descending artery was patent. Balloon angioplasty restored vessel patency (fig. 2
The development of DES has ushered in a new era in PCI due to the significantly lower rate of in-stent restenosis2,3
and no apparent increase in risk. After US Food and Drug Administration approval in April 2003, DES have rapidly become the stent of choice for the approximately 1 million PCI performed each year in the United States. It is clear that interruption of dual antiplatelet therapy is known to carry a high risk of stent thrombosis with significant mortality.4
Therefore, if possible, surgery should be delayed to allow completion of the recommended course of dual antiplatelet therapy. When preoperative cardiac testing reveals a need for PCI, the appropriate choice of stent is dictated by the urgency of the planned surgery.5
Recently, there has been gathering evidence that late stent thrombosis may be occurring at a higher rate in DES.6,7
Late stent thrombosis in bare metal stents is extremely rare in the absence of intracoronary radiation. The risk of late stent thrombosis with bare metal stents lessens over time, presumably due to endothelialization of the stent. However, the risk of late stent thrombosis in DES seems to persist and is associated with a high mortality rate. Predictors of stent thrombosis include premature cessation of antiplatelet therapy, bifurcation lesions, renal failure, and low ejection fraction.6
In September 2006, the Food and Drug Administration released a statement saying that they are “aware of a small but significant increase in the rate of death and myocardial infarction possibly due to stent thrombosis in patients treated with DES … At this time the Food and Drug Administration believes that coronary DES remain safe and effective when used for approved indications …”§
that established the efficacy of DES versus
bare metal stents in the reduction of restenosis were confined to low-risk lesions. The reality of clinical practice is that a large number of PCI with DES occurs as off-label use in patients with high-risk lesions (lesion type or patient comorbidity) where the incidence of stent thrombosis is believed to be higher and the reduction in the rate of restenosis is attenuated.
Against this backdrop, the implications for the perioperative period are significant. Our patient was 29 months removed from DES placement and 17 months removed from stopping clopidogrel. Recommendations to continue clopidogrel for 12 months after DES placement8
would not have impacted our patient, who had completed 1 yr of dual antiplatelet therapy. McFadden et al.9
reported four cases of late stent thrombosis (average 12 months) after stopping aspirin. Three of the cases occurred when aspirin was stopped preoperatively.
More than 3 million patients in the United States have DES, and many of them will present for surgery after having completed dual antiplatelet therapy. Therefore, we believe that our patient represents a common clinical scenario of underappreciated risk. Guidelines for perioperative management after completion of dual antiplatelet therapy do not exist at this time. The combination of stopping aspirin and the prothrombotic state induced by surgery likely caused stent thrombosis. Our case demonstrates that patients with DES are not free from risk after they have completed their regimen of dual antiplatelet therapy. On the contrary, the risk of stent thrombosis persists and can lead to major perioperative morbidity. We urge physicians caring for such patients to exercise extreme caution when considering stopping aspirin preoperatively, and we eagerly await guidelines for the treatment of DES patients in the perioperative period.
(Since the acceptance of this case report for publication, the following document has been released: Grines CL, Bonow RO, Casey DE Jr, Gardner TJ, Lockhart PB, Moliterno DJ, O’Gara P, Whitlow P: Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: A science advisory from the American Heart Association, American College of Cardiology, Society of Cardiovascular Angiography and Interventions, American College of Surgeons and American Dental Association, with representation from the American College of Physicians. Circulation 2007; 115:813–8)
1. Smith SC, Feldman TE, Hirshfeld JW, Jacobs AK, Kern MJ, King SB III, Morrison DA, O’Neill WW, Schaff HV, Whitlow PL, Williams DO, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B: ACC/AHA Task Force on Practice Guidelines and ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: A report of the ACC/AHA Task Force Practice Guidelines. Circulation 2006; 113:e166–286
2. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O’Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE, SIRIUS Investigators: Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery N Engl J Med 2003; 349:1315–23
3. Stone GW, Ellis SG, Cox DA, Hermiller J, O’Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME, TAXUS-IV Investigators: A polymer-based paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350:221–31
4. Kaluza GL, Joseph J, Lee JR, Raizner ME, Raizner AE: Catastrophic outcomes of noncardiac surgery soon after coronary stenting. J Am Coll Cardiol 2000; 25:1288–94
5. Satler LF: Recommendations regarding stent selection in relation to the timing of noncardiac surgery postpercutaneous coronary intervention. Catheter Cardiovasc Interv 2004; 63:146–7
6. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, Airoldi F, Chieffo A, Montorfano M, Carlino M, Michev I, Corvaja N, Briguori C, Gerckens U, Grube E, Colombo A: Incidence, predictors and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 293:2126–30
7. Pfisterer M, Brunner-La Roca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C, Jeger R, Bader F, Osswald S, Kaiser C: Late clinical events after clopidogrel discontinuation may limit the benefits of drug-eluting stents. J Am Coll Cardiol 2006; 48:2584–91
8. Silber S, Albertsson P, Aviles FF, Camici PG, Colombo A, Hamm C, Jorgensen E, Marco J, Nordrehaug JE, Ruzyllo W, Urban P, Stone GW, Wijns W, Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology: Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005; 26:804–47
9. McFadden EP, Stabile E, Regar E, Cheneau E, Ong ATL, Kinnaird T, Suddath WO, Weissman NJ, Torguson R, Kent KM, Pichard AD, Satler LF, Waksman R, Serruys PW: Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004; 364:1519–21
§ US Food and Drug Administration Statement on Coronary Drug-Eluting Stents. Available at: http://www.fda.gov/cdrh/news/091406.html
. Accessed September 14, 2006. Cited Here...
This article has been cited 10 time(s).
Journal of Cardiothoracic and Vascular AnesthesiaDrug-Eluting Stents: Patient Understanding of the Risks of Premature Cessation of Antiplatelet DrugsJournal of Cardiothoracic and Vascular Anesthesia
CirculationSafety of Short-Term Discontinuation of Antiplatelet Therapy in Patients With Drug-Eluting StentsCirculation
Anaesthesia, Pain, Intensive Care and Emergency: A.P.I.C.E
Use and misuse of preoperative cardiac testing for noncardiac surgery
Anaesthesia, Pain, Intensive Care and Emergency: A.P.I.C.E, ():
Jacc-Cardiovascular InterventionsPerioperative Management of Patients With Drug-Eluting StentsJacc-Cardiovascular Interventions
Journal of Clinical AnesthesiaIntraoperative drug-eluting stent thrombosis in a patient undergoing robotic prostatectomyJournal of Clinical Anesthesia
Anesthesia and AnalgesiaCoronary artery stents: II. Perioperative considerations and managementAnesthesia and Analgesia
British Journal of AnaesthesiaDrug-eluting stent thrombosis in patients undergoing non-cardiac surgery: is it always a problem?British Journal of Anaesthesia
European Journal of Anaesthesiology (EJA)The patient with coronary stents and antiplatelet agents: what to do and how to deal?European Journal of Anaesthesiology (EJA)
AnesthesiologyDrug-eluting Coronary Stents: What Are the Risks?Anesthesiology
Current Opinion in AnesthesiologyAnaesthesia in patients with drug-eluting stentsCurrent Opinion in Anesthesiology
© 2007 American Society of Anesthesiologists, Inc.
Publication of an advertisement in Anesthesiology Online does not constitute endorsement by the American Society of Anesthesiologists, Inc. or Lippincott Williams & Wilkins, Inc. of the product or service being advertised.